What is DiogenX?
DiogenX is a preclinical stage biotechnology company dedicated to discovering and developing innovative biologics for diabetic patients. Its core mission revolves around creating new therapeutic options to address the millions affected by diabetes worldwide. The company's lead program, stemming from research by Dr. Patrick Collombat, employs a novel strategy to stimulate beta-cell functional recovery, aiming to rebalance glucose/insulin homeostasis. This unique mode of action promises a distinct solution for managing diabetes, with the potential for significant clinical benefits.
How much funding has DiogenX raised?
DiogenX has raised a total of $30.3M across 1 funding round:
Series A
$30.3M
Series A (2023): $30.3M with participation from Omnes Capital, Boehringer Ingelheim Venture Fund, JDRF T1D Fund, and Eli Lilly and Company Pvt
Key Investors in DiogenX
Omnes Capital
Omnes Capital is a European private equity firm specializing in energy transition and deeptech innovation, managing over 6.7 billion euros and supporting entrepreneurs in sustainable growth.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in first-in-class therapeutics across various modalities, driving innovation in pharmaceutical R&D with a global reach.
JDRF T1D Fund
The T1D Fund is a venture impact fund dedicated to accelerating treatments and cures for Type 1 Diabetes, investing in innovative therapies and reinvesting returns to foster progress.
What's next for DiogenX?
With the recent influx of major strategic investment, DiogenX is poised to advance its preclinical pipeline and further its mission to combat diabetes. The substantial enterprise-level funding provides the necessary capital to progress its innovative beta-cell regeneration program through critical development stages. This strategic backing from prominent investors in the life sciences and venture capital sectors signals strong confidence in DiogenX's scientific approach and market potential. The company is expected to focus on key milestones, including further preclinical validation and potential progression towards clinical trials, solidifying its position in the competitive diabetes therapeutics landscape.
See full DiogenX company page
